Technical Analysis for CGON - CG Oncology, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | 0.00% | |
| MACD Bullish Centerline Cross | Bullish | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| 50 DMA Support | Bullish | 1.07% | |
| Stochastic Reached Overbought | Strength | 1.07% | |
| Multiple of Ten Bullish | Other | 1.07% | |
| Overbought Stochastic | Strength | 1.07% | |
| Upper Bollinger Band Touch | Strength | 1.07% | |
| 50 DMA Support | Bullish | -6.23% | |
| Pocket Pivot | Bullish Swing Setup | -6.23% |
| Alert | Time |
|---|---|
| 50 DMA Support | about 12 hours ago |
| 60 Minute Opening Range Breakdown | about 16 hours ago |
| Down 3% | about 16 hours ago |
| Fell Below 50 DMA | about 16 hours ago |
| Fell Below Previous Day's Low | about 16 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
CG Oncology formerly known as Cold Genesys is a privately held, clinical-stage biopharmaceutical company that focuses on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already been completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Virotherapy Immunotherapies Oncolytic Virus
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Virotherapy Immunotherapies Oncolytic Virus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 50.23 |
| 52 Week Low | 28.55 |
| Average Volume | 528,023 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 39.94 |
| 20-Day Moving Average | 38.04 |
| 10-Day Moving Average | 37.79 |
| Average True Range | 2.71 |
| RSI (14) | 54.95 |
| ADX | 17.04 |
| +DI | 26.06 |
| -DI | 20.18 |
| Chandelier Exit (Long, 3 ATRs) | 35.84 |
| Chandelier Exit (Short, 3 ATRs) | 41.54 |
| Upper Bollinger Bands | 42.68 |
| Lower Bollinger Band | 33.41 |
| Percent B (%b) | 0.78 |
| BandWidth | 24.36 |
| MACD Line | 0.11 |
| MACD Signal Line | -0.50 |
| MACD Histogram | 0.6158 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 45.24 | ||||
| Resistance 3 (R3) | 45.08 | 43.38 | 44.47 | ||
| Resistance 2 (R2) | 43.38 | 42.20 | 43.46 | 44.21 | |
| Resistance 1 (R1) | 42.00 | 41.48 | 42.69 | 42.16 | 43.96 |
| Pivot Point | 40.30 | 40.30 | 40.65 | 40.38 | 40.30 |
| Support 1 (S1) | 38.92 | 39.12 | 39.61 | 39.08 | 37.28 |
| Support 2 (S2) | 37.22 | 38.40 | 37.30 | 37.03 | |
| Support 3 (S3) | 35.84 | 37.22 | 36.77 | ||
| Support 4 (S4) | 36.00 |
